BioSpace News Archive

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate on a panel of top innovators in anti-infective drug development as part of Maxim Group’s M-VEST Virtual Conference Series. Date: Thursday, September 17, 2020 Panel details: A discussion among CEOs of top anti-fungal innovators, moderated by Maxim Group analyst, Jason McCarthy, Ph.D. Time

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced three presentations for its TransCon PTH program for hypoparathyroidism (HP) at the American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting Virtual Event, taking place September 11–15. In addition, results from the randomized, double-blind phase 2 PaTH Forw

Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that Michael F. Cola, President and Chief Executive Officer, will present at two upcoming virtual conferences. H.C. Wainwright 22nd Annual Global Investment Conference Date: Monday, September 14, 2020 Time: 3:00 PM ET Oppenheimer Fall Heal

MISSISSAUGA, Ontario, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix ® ), an award-winning life sciences innovator and exporter, is pleased to announce attainment of Australian Therapeutic Goods Administration (TGA) registration for its COVID-19 and high-risk HPV quality assessment products (QAPs™) – TGA registration of these REDx™ Controls & REDx™FLOQ ® products by Microbix’s distributor, R-Biopharm, enables it to offer these workflow contro

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the completion of the ANAVEX ® 2-73 ( blarcamesine ) U.S. Phase 2 study in Rett syndrome. The Com

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in two upcoming virtual investor conferences. Presentation Details: Event: Morgan Stanley 18 th Annual Global Health

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Officer, will present in two upcoming virtual conferences in September. Cantor Virtual Healthcare Conference Date: Tuesday, September 15 Time: 4:40 PM Eastern Time H.C. Wainwright 22nd Annual Global Investment Conference Date

Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced the election of Rashmi Kumar, age 51, to its Board of Directors, effective immediately, expanding the Board to 12 members. Additionally, Ms. Kumar was appointed to the Audit and Finance Committee of Myriad’s Board. Ms. Kumar is Senior Vice President and Global Chief Information Officer of Hewlett

Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced the appointment of William H. Carson, M.D., to its Board of Directors. “Bill knows how to drive the development of innovative treatments — including drugs for a wide range of diseases that affect the brain — from concept to commercialization,” said Franc

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will present clinical data on AXS-05 in the treatment of major depressive disorder (MDD) at the 33 rd Congress of the European College of Neuropsychopharmacology (ECNP), to be held virtually, September 12-15. AXS-05 (dextromethorphan/bupropion modulated delivery tablet